• Men Who Often Miss Their Prostate Cancer Screening Appointments are a lot of like to die from the Disease, According to New Findings.
  • The Analysis, Based on 20 Years of Data from Over 160,000 Men Across Seven European Countries, Highlights A Newly identified High-Risk Group Offten Overloked in National Screening Efforts.
  • Researchers Say Understanding and Addressing Why Sub Men Avoid Screening Could Be Key To Improving Survival Rates and The Overall Success of Future Prostate Cancer Screening Program.

Prostate Cancer is The Most Commonly Diagnosed Cancer Among Men In 112 Countries, and its prevalence is projected to double by 2040.

Nationally implemented screening program that measure prostate-specific antigen (PSA) Levels in the Blood Coud Offer Men Earlier Access to Treatment, Improving their chances of a cure and reducing the need for expense treatments linked to advanced-tage disease.

Long-Term Data Consistently Show That PSA Screening Can Lower The Risk of Dying From Prostate Cancer by 20%.

In This New Research, From The World’s Larganest Prostate Cancer Screening Study, However, Refrachers Looked at 20 Years of Data To See How Often Saying No To Prostate Cancer Screening Affects The Chances of Dying From The Disease.

Based on 20 Years of Data from Over 160,000 Men Across Seven European Countries, The Study Highlightd A High-Risk Group OFTEN OVERLOKED IN NATIONAL SCREENING EFFORTS: APPOINTMENT AVOIDERS.

The Study’s Findings Showed That Over 12,400 People Skipped their Prostate Screening Appaintments, Leading to 45% Higher Risk of Death from Prostate Prostate Cancer

The Findings were present at the European Association of Urology Congress 2025, March 21–24, In Madrid, Spain.

Why Men Avoid Prostate Cancer Screenings

Choking not to take part in screening may stem from a Complex Combination of Factors, According to the Study’s Lead Author, Renée Leenen, MD, and Phd Research in Professor Monique Roobol’s Team at The Erasmus Mc Cancer Institute.

“The European Randomized Study of Screening for Prostate Cancer (ERSPC) was Initiedated in the Early 1990s to Assess The Effect of Prostate-Specific Antigen (PSA) -Based Screening on Prostate Cancer (PCA) Mortality at A Population Level. GET INSIGHT INTO THE RISK OF DYING OF PCA IN LEAD Medical News Today.

“In the ERSPC, Men Were Randomized to Eithher a Screening ARM (Invited for Screening/PSA Test) Or control ARM (not offered screening/Psa Test),” Leenen Continued.

“Of the 72,460 Men Randomized to the SA, 12,401 (17%) Did Not Attend Any of The Screening Rounds Offered. We Found That Men Who Were Offered Screening (Randomised to The Screening Arm) But Did Not Atten Population-Based Screening (Screening Arm Non-Attenders) are 39% Higher Risk of Dying from PCA Comparked to Men That Were Not Offered Screening (In The Control Arm). ”

– Renée Leenen, MD

“As A Concequence, Non-Atonce May Be the Biggest Counteracting Factor To The Successful Implementation of Population-Based Screening Program for (Prostate) Cancer,” Leenen Explained.

Niles Vora, MD, Board-Certified Hematologist and Medical Oncologist and Medical Director of the Memorialcare Todd Cancer Institute at Long Beach Medical Center in Long Beach, CA, Not Involved in This Research, described these New Findings as “Fascinating.

Lower Death Risk by Attending Screenings

“There have long been controversy over whether psa screening is Helpful in a ease In screening. “

– Niles Vora, MD

“The Age of the Population at Hand-55-69 Represents One That Are Candidates For AgragSive Treatments If Prostate Cancer is Found and Thus, Should Be The Target for Prostate Cancer Screening in Future Studies That Could Validate This Trial,” Vora Note.

Although these results are yet to be peer-reavewed, vora is looking forward to the full results being publiad late This Year.

70% of the Population Needs to Be Screened, Says Who

“For Any Screening Program to Be Effective, The World Health Organization (WHO) Recommends that 70% of the Population Needs to be exposed to the screening test,” Leenen Poined out.

“Nevertheless, Current Cancer Screening Program Low and Declineing Participation Rates,” He noted.

Non-Atonce May Also Be One of the Biggest Counteracting Factors When it comes to Successful Screening for Prostate Cancer.

“We Found That Men Who was offered screling but Did not attend population-base screening are at higher risk of dying from pca compared to men that were not offered screening. Population-Based Screening Programmes for (Prostate) Cancer. ”

– Renée Leenen, MD

“Hennce, There is an urgent need for further qualitative research to explore screening non-Attenders and Understand Why, Although Being offered screening, they opted not to attend population-base screening,” Leenen Explained.

“This could informs Tailored Intervention to Address Awareness, Reported Participation and Inequalities in Access,” Dr. Leened Added.

Why Prostate Cancer Screening Rates Were Low

In 2012The US Preventive Services Task Force Discoured People From Undergoing Prostate-Specific Antigen (PSA) -Based Prostate Cancer Screening Due to Overteratment and Overdiagnosis From The Years Before. However, Later data Showed That Lower Screening Rates Were Linked to An Increase in Advanced Cancers.

Ramkishen Narayanan, MD, Board Certified Urologist and Urologic Oncologist and Director of the Center for Urologic Health at The Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center in Burbank, CA, WHO WAS ALSO NOT INVOLVED TOLD MNTSaid That “The European Randomized Study of Screening for Prostate Cancer (ERSPC) You have Been a Touchstone for the importance of prostate cancer screening in the us for over 10 years now.”

“This Updated Study from Our European Colleagues continues to highlight the importance of prostate cancer screening in preventing prostate cancer-related Deaths,” He Said.

“The Initial Erspc Study (Schröder et al., 2014) Reported us that if you perform a PSA Screening Blood Test in About 1,000 men, You Will End Up Diagnosing and Treating 37 Men To Prevent One Prostate Cancer-Reatized Death,” Narayan Explained.

“Take at face Value This May not appear VERY Impressive and Historically There Was Over-Reatment of Prostate Cancer in the Us, Specifying Men Diagnosed With Low Risk Prostate Cancer Getting Surgery or Radiation and ‘Suffering in silence Narayan Said.

“The concern to potentially unnecessarry surgery or radiation led to an over-correction where prostate cancer screening was discouraged in the us from 2012 to 2017 by the United States Preventive Services Task Force (USPSTF). Time journal to prostate cancer getting diagnosed at Higher Grades and Stages, ”I have continued.

“In This Updated, Erspc Study, The Take-Home Point Is That The Over 12,000 Men Who Effectively Did not follow screening reduces The Risk of Dying from Prostate Cancer. “

– Ramkishen Narayanan, MD

“What is Still Left Up To Interpretation is the best practical Application of Psa Screening for the average Empowered to start and stop psa screening with the guidance of their trusted Physician, ”Narayanan Noted.

WHY YOU SHOULDN’T SKIP A SCREENING

“Prostate cancer screening trials and population-base screling program/Events were used in the us in the past but fell out of favor to the undisciplined management of results and subsequent treatment. In the contemporary era, where patients are more report to the point of Being Inundated With Recommendations, I Believe The Study Here Sends to Clear Signal Through the Noise – Ignoring Prostate Cancer Screening Will Significantly Increases Man’s Risk of Dying from Prostate Cancer. ”

– Ramkishen Narayanan, MD